Document Detail


Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95-sensitive cells.
MedLine Citation:
PMID:  11640888     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CD178 (CD95-ligand) is expressed on several tumor cells and likely influences the interaction of the tumor with the host immune system. However, little is known about the mechanisms that regulate its expression on the cell surface. We have evaluated the ability of various compounds and cytokines to regulate cell surface expression and release of soluble CD178 in various carcinoma cell lines. Vitamin E succinate (VES) and retinoic acid (RA) were found to reduce CD178 surface expression, whereas interferon-gamma stimulated a slight upregulation. At 48 h, the regulation of surface CD178 by VES and RA arose from a small decrease in CD178 mRNA and to a greater extent due to an increase in the release of soluble CD178; the latter was blocked by addition of a metalloproteinase inhibitor. Accordingly, VES and RA treatment diminished the ability of tumor cells to kill CD95-sensitive cells and this effect was markedly reduced by the presence of a metalloproteinase inhibitor. Our results indicate that, in vitro, CD178 expression on the cell surface of tumor cells can be regulated by agents that alter both expression and release of the ligand. In vivo, such treatments may play an important role in the outcome of tumor sensitivity or resistance to host immune mechanisms.
Authors:
H R Salih; G C Starling; M Knauff; M B Llewellyn; P M Davis; W J Pitts; A Aruffo; P A Kiener
Related Documents :
23930208 - A phase i study of abt-510 plus bevacizumab in advanced solid tumors.
8633088 - Resistance of k-rasbv12 proteins to farnesyltransferase inhibitors in rat1 cells.
11778648 - Relationship of the k-ras/c-mos expression patterns with angiogenesis in non-small cell...
8356338 - Cell proliferation and prevalence of ras gene mutations in 7,12-dimethylbenz(a)anthrace...
10721958 - Combination of clinical factors predictive of growth of small choroidal melanocytic tum...
3881168 - Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Experimental cell research     Volume:  270     ISSN:  0014-4827     ISO Abbreviation:  Exp. Cell Res.     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-10-19     Completed Date:  2001-12-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0373226     Medline TA:  Exp Cell Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  248-58     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Academic Press.
Affiliation:
Department of Immunology, Inflammation and Pulmonary Diseases, Pharmaceutical Research Institute, Princeton, New Jersey 08540, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Antioxidants / pharmacology*
Apoptosis / drug effects*,  immunology
Coculture Techniques
Fas Ligand Protein
Female
Flow Cytometry
Gene Expression Regulation, Neoplastic / drug effects
HT29 Cells
Humans
Immune System / physiology
Jurkat Cells
Lung Neoplasms
Male
Membrane Glycoproteins / genetics*,  metabolism
Ovarian Neoplasms
Prostatic Neoplasms
RNA, Messenger / analysis
Tretinoin / pharmacology*
Vitamin E / pharmacology*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Antioxidants; 0/FASLG protein, human; 0/Fas Ligand Protein; 0/Membrane Glycoproteins; 0/RNA, Messenger; 1406-18-4/Vitamin E; 302-79-4/Tretinoin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Control of intracellular movement of connexins by E-cadherin in murine skin papilloma cells.
Next Document:  Integrin- and cadherin-mediated induction of the matrix metalloprotease matrilysin in cocultures of ...